CellWell record HH-207599
Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence
Yang, Xiu Hong; Liu, Yao; Fu, Chen Sheng; Jin, Hui Min; Ye, Zhi Bin
Frontiers (Publisher) · 2026
In plain language
Anti-TGF-β1 and anti-VEGF-B monoclonal antibodies failed phase II diabetic kidney disease trials, whereas PCSK9 antibodies appear more promising.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-207599
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.